- Home
- CORT
as 11-25-2025 3:38pm EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $139.00 | AVG Volume (30 days): | 639.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.87 | EPS Growth: | -30.72 |
| 52 Week Low/High: | $49.00 - $117.33 | Next Earning Date: | 11-04-2025 |
| Revenue: | $741,172,000 | Revenue Growth: | 17.92% |
| Revenue Growth (this year): | 28.85% | Revenue Growth (next year): | 34.98% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Guyer William | CORT | Chief Development Officer | Nov 5 '25 | Sell | $75.56 | 20,000 | $1,507,121.70 | 5,287 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Nov 5 '25 | Sell | $75.10 | 28,782 | $2,152,105.36 | 2,755,797 | |
| Lyon Joseph Douglas | CORT | See Remarks | Nov 3 '25 | Sell | $73.65 | 5,000 | $368,244.50 | 10,277 | |
| Maduck Sean | CORT | See Remarks | Nov 3 '25 | Sell | $73.99 | 20,000 | $1,479,816.00 | 7,904 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Nov 3 '25 | Sell | $74.08 | 11,218 | $831,013.73 | 2,755,797 | |
| Swisher Daniel N JR | CORT | Director | Oct 10 '25 | Sell | $87.54 | 2,200 | $192,588.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Oct 7 '25 | Sell | $89.94 | 20,000 | $1,798,782.00 | 5,287 | |
| Swisher Daniel N JR | CORT | Director | Sep 10 '25 | Sell | $72.45 | 2,200 | $159,390.00 | 0 | |
| Lyon Joseph Douglas | CORT | See Remarks | Sep 2 '25 | Sell | $70.50 | 5,000 | $351,247.44 | 10,277 | |
| Maduck Sean | CORT | See Remarks | Sep 2 '25 | Sell | $70.61 | 20,000 | $1,409,828.00 | 7,904 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Corcept Therapeutics (CORT): Evaluating Valuation Following Impressive Recent Share Price Gains
StockStory
4 days ago
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
Business Wire
a month ago
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
StockStory
a month ago
3 High-Flying Stocks We Approach with Caution
Simply Wall St.
a month ago
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed
StockStory
2 months ago
3 Profitable Stocks That Concern Us
StockStory
2 months ago
Why Corcept (CORT) Shares Are Falling Today
MT Newswires
2 months ago
Corcept Therapeutics Insider Sold Shares Worth $1,798,782, According to a Recent SEC Filing
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.